Synthetic biology is a composite of science and engineering that culminates in the design and invention of new organisms or alteration of living systems through the amalgamation of molecular biology, genetic engineering, and genomics. This is a major technological breakthrough that facilitates the creation of DNA and even whole genomes for use in biofuels, bio-products, renewable chemicals, specialty chemicals, and healthcare fields, thereby making the entire industries to walk in step with one another.
Key Growth Drivers and Opportunities
Increasing Involvement of Government Bodies: Widened authorities and research institutions involvement, more money for R&D projects, decreasing DNA synthesis prices, increasing food demand and several genome engineering breakthroughs as CRISPR technique are the major factors that have given rise to the synthetic biology global market. However, this trend is still somewhat restrained by the existence of several issues such as doubts in biosafety and bioethics, the danger of unplanned release of pathogens, and the complexity of designing and verifying biological systems.
Challenges
Synthetic biology market is limited by several factors including ethical and biosafety issues, the danger of the unintentional release of pathogens, high complexity in designing and testing biological systems, regulatory difficulties, and the possibility of malicious use, thereby slowing down the market expansion and adoption.
Innovation and Expansion
Cusat has Launched India’s First MTech in Synthetic Biology and Biomanufacturing
In August 2025, Cochin University of Science and Technology (Cusat), in collaboration with the CVJ Centre for Synthetic Biology and Biomanufacturing, launched India’s first MTech programme in Synthetic Biology and Biomanufacturing, marking a significant step toward shaping the country’s biotechnology future.
This cutting-edge two-year postgraduate programme solidifies India’s position on the global map of advanced biotech education, preparing students to design organisms, develop biological systems, and scale biomanufacturing processes that power the world’s fastest-growing bioeconomy.
Ribbon Bio Introduces MiroSynth DNA Molecules, Ushering in a New Era of Complex Synthetic DNA
In May 2025, Ribbon Bio GmbH, a DNA synthesis firm, has announced the release of MiroSynth DNA, its first commercial product aimed at meeting the growing need for complex and highly accurate synthetic DNA molecules.
MiroSynth DNA is based on Ribbon’s proprietary algorithm-driven technology and precision enzymatic assembly method, which provide remarkable accuracy and performance for applications in biopharma, life sciences, and academic research. Customers and partners in the United States, Europe, the United Kingdom, and Australia can now use MiroSynth DNA to advance their most ambitious scientific projects.
Inventive Sparks, Expanding Markets
The players who globally operate in the synthetic biology market are Thermo Fischer Scientific, GenScript, Biosearch Technologies, Integrated DNA technologies, Eurofins Scientific, Inc., Origene technologies, Scientific genomics Inc., Editas Medicine, Inc., Pareto Biotechnologies and Syntrox Inc.
About Author:
Prophecy is a specialized market research, analytics, marketing and business strategy, and solutions company that offer strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high value opportunities in the target business area. Also, we help our client to address business challenges and provide best possible solutions to overcome them and transform their business.
